Survodutide Calculator
Survodutide (also known as BI 456906) reconstitution and dosage reference — calculate vial concentration, BAC water volume, and exact syringe units below.
At the reference preset of a 10mg Survodutide vial reconstituted with 2 mL of bacteriostatic water, a 1.2mg dose measures 24 units on a U-100 insulin syringe.
Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma.
- Concentration
- 5 mg/mL
- Draw volume
- 0.24 mL
- Units (U-100)
- 24
- Doses per vial
- ≈ 8
- Reference preset
- 10mg · 2mL · 1.2mg
Reference values from the default preset — adjust the calculator below for your vial.
What is Survodutide?
Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 obesity trials reported up to 19% mean weight loss at the highest dose. As of April 2026 it remains investigational.
| 6 mg | lyophilized powder |
| 10 mg | lyophilized powder |
| 0.6 mg | ≈ 12 U-100 units (at 10mg / 2mL) |
| 1.2 mg | ≈ 24 U-100 units (at 10mg / 2mL) |
| 2.4 mg | ≈ 48 U-100 units (at 10mg / 2mL) |
| 3.6 mg | ≈ 72 U-100 units (at 10mg / 2mL) |
| 4.8 mg | ≈ 96 U-100 units (at 10mg / 2mL) |
How it's typically prepared
Reconstitute with BAC water; refrigerate.
Frequently asked questions
- Is survodutide approved?
- No — as of April 2026 survodutide is in late-phase clinical trials and not commercially available outside trial settings.
Other GLP-1 peptides
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.